Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP716765.RAwlhwW7J9m-gaDbzi-EmhYj6zBbLf5rr7rNbYlqRra-o130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP716765.RAwlhwW7J9m-gaDbzi-EmhYj6zBbLf5rr7rNbYlqRra-o130_assertion type Assertion NP716765.RAwlhwW7J9m-gaDbzi-EmhYj6zBbLf5rr7rNbYlqRra-o130_head.
- NP716765.RAwlhwW7J9m-gaDbzi-EmhYj6zBbLf5rr7rNbYlqRra-o130_assertion description "[A biological assay combined with high pressure liquid chromatography-tandem mass spectrometry showed that plasma and cerebral spinal fluid (CSF) PAF levels in 20 patients with relapsing/remitting or secondary progressive multiple sclerosis (MS) studied by magnetic resonance imaging (MRI) were significantly higher than in healthy controls (plasma: 3.29+/-4.52 vs. 0.48+/-0.36 ng/ml, p < 0.002; CSF: 4.95+/-6.22 ng/ml vs. 0.01+/-0.04 ng/ml, p < 0.0001).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP716765.RAwlhwW7J9m-gaDbzi-EmhYj6zBbLf5rr7rNbYlqRra-o130_provenance.
- NP716765.RAwlhwW7J9m-gaDbzi-EmhYj6zBbLf5rr7rNbYlqRra-o130_assertion evidence source_evidence_literature NP716765.RAwlhwW7J9m-gaDbzi-EmhYj6zBbLf5rr7rNbYlqRra-o130_provenance.
- NP716765.RAwlhwW7J9m-gaDbzi-EmhYj6zBbLf5rr7rNbYlqRra-o130_assertion SIO_000772 10376955 NP716765.RAwlhwW7J9m-gaDbzi-EmhYj6zBbLf5rr7rNbYlqRra-o130_provenance.
- NP716765.RAwlhwW7J9m-gaDbzi-EmhYj6zBbLf5rr7rNbYlqRra-o130_assertion wasDerivedFrom befree-20140225 NP716765.RAwlhwW7J9m-gaDbzi-EmhYj6zBbLf5rr7rNbYlqRra-o130_provenance.
- NP716765.RAwlhwW7J9m-gaDbzi-EmhYj6zBbLf5rr7rNbYlqRra-o130_assertion wasGeneratedBy ECO_0000203 NP716765.RAwlhwW7J9m-gaDbzi-EmhYj6zBbLf5rr7rNbYlqRra-o130_provenance.